Post-CDK4/6i wars in HR+/HER2− breast cancer: is elacestrant a solid contender through the lens of precision oncology
@article{ACTR11071,
author = {Ünal Metin Tokat and Nalan Babacan and Mutlu Demiray},
title = {Post-CDK4/6i wars in HR+/HER2− breast cancer: is elacestrant a solid contender through the lens of precision oncology},
journal = {AME Clinical Trials Review},
volume = {3},
number = {0},
year = {2025},
keywords = {},
abstract = {},
issn = {3005-6152}, url = {https://actr.amegroups.org/article/view/11071}
}